Table 2

Study schedule of assessments

Study period
EnrolmentAllocationInterventionFollow-up
Time point−3~0 days07~14 days1, 3 and 6 months
ENROLMENT:X   
Eligibility screenX   
Informed consentX   
Allocation X  
INTERVENTIONS:    
XST treatment  X 
Placebo treatment  X 
ASSESSMENTS:    
MACE  XX
CK-MB XX 
cTnT XX 
cTnI XX 
hsTnI XX 
Adverse events  XX

  • CK-MB, creatine kinase MB; cTnI, cardiac troponin I; cTnT, cardiac troponin T; hsTnI, high-sensitivity troponin I; MACE, major adverse cardiac events; UA, unstable angina; XST, Xueshuantong injection.